Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Payables: 2009-2025

Historic Payables for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $40.4 million.

  • Northwest Biotherapeutics' Payables rose 58.67% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 67.15%. This contributed to the annual value of $31.2 million for FY2024, which is 119.59% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Payables stood at $40.4 million, which was up 1.18% from $40.0 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Payables' 5-year high stood at $40.4 million during Q3 2025, with a 5-year trough of $9.7 million in Q1 2021.
  • Its 3-year average for Payables is $27.8 million, with a median of $25.5 million in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Payables tumbled by 45.62% in 2023, and later skyrocketed by 119.59% in 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Payables (Quarterly) stood at $14.1 million in 2021, then spiked by 85.30% to $26.1 million in 2022, then plummeted by 45.62% to $14.2 million in 2023, then spiked by 119.59% to $31.2 million in 2024, then skyrocketed by 58.67% to $40.4 million in 2025.
  • Its Payables stands at $40.4 million for Q3 2025, versus $40.0 million for Q2 2025 and $40.4 million for Q1 2025.